HUTCHMED Initiates Global Strategic Collaboration with Otsuka on BCMAxCD3 Bispecific T-cell Engager (HBM7020) for Autoimmune Diseases

Zhitrans Financial APP reports that Hapten Pharma-B (02142) has announced that the group has entered into a global strategic collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ("Otsuka") to advance the BCMAxCD3 bispecific T cell engager HBM7020 for the treatment of autoimmune diseases. Under this agreement, Otsuka has been granted exclusive rights to develop, manufacture, and commercialize HBM7020 globally (excluding the Greater China region, namely mainland China, Hong Kong, Taiwan, and Macao).